All In Biotech

Drug Trial Radar · NCT07002905

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Jul 3, 2025

Primary completion

Dec 8, 2025

Study completion Dec 8, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.

Conditions

  • Chronic Weight Management

Interventions

  • ASC30 tablets or ASC30 tablets A1 or placeboDrug

    Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from Baseline up to Week 13Time frame: Baseline and Week 13

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ascletis Clinical Site

    Rogers, Arkansas

  • Ascletis Clinical Site

    Fort Myers, Florida

  • Ascletis Clinical Site

    Miami, Florida

  • Ascletis Clinical Site

    Columbus, Ohio

  • Ascletis Clinical Site

    Bellaire, Texas

  • Ascletis Clinical Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.